BIO Submits Comments to CMS Regarding the End-Stage Renal Disease Prospective Payment System Proposed Rule

August 29, 2014
 
BY ELECTRONIC DELIVERY
 
Marilyn Tavenner
Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
Room 445-G
Hubert H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201
 
Re: Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies [CMS–1614–P]
 
Dear Administrator Tavenner:
 
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’s) proposed rule regarding payment policies under the End-Stage Renal Disease Prospective Payment published in the Federal Register on July 11, 2014 (the “Proposed Rule”).1 BIO represents more than 1,000 biotechnology companies, state biotechnology centers, academic institutions, and related organizations both in the United States and abroad. BIO members are critical contributors to the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.